← brief for 2026-08-13 · Slowing decline

Targeted-release Budesonide (Nefecon) versus systemic glucocorticoids for IgA nephropathy: a placebo-anchored indirect treatment comparison of randomized controlled trials

Paper B Peer reviewed Small trial

Key takeaways

This review of three trials compared Nefecon to standard steroids for IgA nephropathy. Nefecon was better at reducing proteinuria (protein in urine) and slowing kidney decline. However, the trials were small: 35-40 patients per group for 24 weeks. This difference might not last in long-term studies.

Who did this work

Jianbo Qing (Sir Run Run Shaw Hospital) · Wenjie Wei (Sir Run Run Shaw Hospital) · Junnan Wu (Sir Run Run Shaw Hospital)

Source

Paper · OpenAlex, Kidney disease concept sweep (verified C2778653478) · 2026-08-12
https://doi.org/10.1186/s12882-026-05251-y